BioSpace News Archive

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2021 financial results and provide a corporate update before market open on Wednesday, March 2, 2022.

BrainsWay Ltd. today announced the publication of results in the Journal of Clinical Medicine further defining the efficacy of the Company’s proprietary Deep TMS™ symptoms.

Rani Therapeutics Holdings, Inc. today announced the development of a high-capacity oral biologics device known as the RaniPill™ HC (High Capacity), capable of delivering up to a 500%-plus higher drug payload than Rani’s existing oral biologics capsule.

aTyr Pharma, Inc. today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will participate in a panel as part of the National Institutes of Health (NIH) Rare Disease Day ® virtual conference on Monday, February 28, 2022, at 2:55pm EST / 11:55am PST.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce that it has appointed leading immunologist, Alexander Kharazi, M.D., Ph.D., to its Scientific Advisory Board.

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), announced today that the 3-year results of the PALADIN study have been published in the peer-reviewed journal Ophthalmology.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced that it has entered into a lease agreement to develop a 140,000-square-foot manufacturing facility in Waltham, Massachusetts, to support the manufacturing of key components for its CRISPR-based investigational therapies.

InnerScope Hearing Technologies Inc. announced the introduction of its own new internal customer call center for its subsidiary HearingAssist of nearly 500,000 customers and its iHear branded hearing aid customers.

Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Lisa Beck as Chief Business Officer.

Poseida Therapeutics, Inc. (NASDAQ: PSTX), today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today beginning at 10:00am ET / 7:00am PT.